(HealthDay News) — Icosapent ethyl (IPE) can further reduce the risk for stroke for statin-treated patients with elevated triglycerides and the risk or evidence of atherosclerosis, according to a study presented at the American Stroke Association International Stroke Conference.
Deepak L. Bhatt, MD, MPH, from Harvard Medical School in Boston, and colleagues conducted a multinational, double-blind trial involving 8179 statin-treated patients with controlled low-density lipoprotein cholesterol, elevated triglycerides, and risk or evidence of atherosclerosis. Participants were randomly assigned to either IPE or placebo. In an earlier trial, the primary composite end point of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina and the key secondary composite end point of cardiovascular death, myocardial infarction, and stroke were reduced by 25 and 26%, respectively; total ischemic events were reduced by 32%.
The researchers found that for IPE versus placebo, event rates for time to first fatal or nonfatal stroke were 2.4 vs 3.3% (hazard ratio, 0.72). Approximately 14 strokes (fatal or nonfatal) were averted for every 1000 patients treated for 5 years with IPE (rate ratio, 0.68). The time to first event rates for ischemic stroke were 2.0 and 3.0% for IPE and placebo, respectively (hazard ratio, 0.64). There was no significant difference noted in the rate of hemorrhagic strokes, which was low for both IPE and placebo (0.3 and 0.2%, respectively).
“Icosapent ethyl is a new way to further reduce the risk of stroke in patients with atherosclerosis or who are at high risk of stroke, who have elevated triglyceride levels and are already taking statins,” Bhatt said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including Amarin Pharma, the manufacturer of icosapent ethyl.